Company intelligence / Profile preview

ViroDefense Inc

Rockville, Maryland, United Statesorpha.net ↗

Ownership: Private
Development stage: Phase 1

Overview

V-073 (pocapavir) showed potent and broad-spectrum anti-poliovirus activity in preclinical studies. V-7404, a direct-acting enterovirus 3C protease inhibitor, completed Phase 1 trials showing acceptable safety and PK profile for treating serious enterovirus infections[1][6].

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (antiviral compounds)
Industry: Biotech

Drug pipeline

1 asset

pocapavir

Unknown

Partnerships

Schering-Plough Corporation (licensed compound series for polio indications)

Beyond the preview

Go deeper on ViroDefense Inc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViroDefense Inc.

Explore the full profile